BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/31/2019 7:02:25 AM | Browse: 781 | Download: 1902
 |
Received |
|
2019-08-03 08:05 |
|
Peer-Review Started |
|
2019-08-03 08:05 |
|
To Make the First Decision |
|
2019-08-28 05:25 |
|
Return for Revision |
|
2019-08-29 09:10 |
|
Revised |
|
2019-09-09 16:30 |
|
Second Decision |
|
2019-09-19 01:53 |
|
Accepted by Journal Editor-in-Chief |
|
2019-09-20 02:56 |
|
Accepted by Executive Editor-in-Chief |
|
2019-09-26 17:17 |
|
Articles in Press |
|
2019-09-26 17:17 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-10-15 00:53 |
|
Typeset the Manuscript |
|
2019-11-14 08:15 |
|
Publish the Manuscript Online |
|
2019-12-31 07:02 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xian-Ze Wang, Zi-Yang Zeng, Xin Ye, Juan Sun, Zi-Mu Zhang and Wei-Ming Kang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Municipal Science and Technology Project |
D171100006517004 |
| CSCO-ROCHE Research Fund |
Y-2019Roche-015 |
|
| Corresponding Author |
Wei-Ming Kang, MD, Chief Doctor, Professor, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, NO.1 of Shuaifuyuan Street, dongcheng District, Bejing 100730, China. kangweiming@163.com |
| Key Words |
Gastric cancer; Locally advanced gastric cancer; Neoadjuvant therapy; Neoadjuvant chemotherapy; Neoadjuvant chemoradiotherapy; NCCN guidelines |
| Core Tip |
Surgical excision is one of the most effective ways in treating nonmetastatic gastric cancer. However, surgery alone cannot achieve satisfactory therapeutic effect in locally advanced gastric cancer (LAGC), and the 5-year survival rate of LAGC patients is less than 50%. The neoadjuvant therapy (NAT) aimed at improving the surgical and R0 resection rate, as well as decreasing the recurrence of micrometastases of LAGC. The strategies of NAT have been continuously developed in the past decades, and the evolvements can be reflected from the vicissitudes of the NCCN guidelines. Moreover, targeted therapy and individualized treatment may be the next hotspots of NAT, and may further improve the prognosis of LAGC patients. |
| Publish Date |
2019-12-31 07:02 |
| Citation |
Wang XZ, Zeng ZY, Ye X, Sun J, Zhang ZM, Kang WM. Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World J Gastrointest Oncol 2020; 12(1): 37-53 |
| URL |
https://www.wjgnet.com/1948-5204/full/v12/i1/37.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v12.i1.37 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
